respiratori
viral
infect
also
known
common
cold
common
infect
human
despit
benign
natur
major
caus
morbid
mortal
worldwid
basi
sever
virus
associ
ill
rhinoviru
common
symptom
product
combin
viral
cytopath
effect
activ
inflammatori
pathway
therefor
antivir
treatment
alon
may
abl
prevent
event
optim
use
agent
also
requir
earlier
initi
therefor
import
develop
accur
rapid
diagnost
techniqu
respiratori
virus
reliabl
effect
treatment
avail
symptomat
therapi
may
remain
possibl
choic
manag
common
cold
commonli
encount
infecti
syndrom
human
be
observ
consid
cold
includ
symptom
rhiniti
variabl
degre
pharyng
major
associ
symptom
includ
nasal
stuffi
discharg
sneez
sore
throat
cough
hoars
voic
patient
frequent
report
chill
signific
high
temperatur
unusu
cold
usual
selflimit
previous
healthi
individu
also
recognis
complic
secondari
bacteri
infect
exacerb
asthma
chronic
obstruct
airway
diseas
cystic
fibrosi
despit
benign
natur
ill
major
case
still
signific
econom
burden
societi
lead
increas
consult
clinician
increas
absenc
school
work
subsequ
caus
loss
earn
although
term
common
cold
tend
impli
singl
caus
ill
fact
caus
anyon
larg
number
antigenet
distinct
virus
tabl
differ
respiratori
virus
utilis
differ
rout
transmiss
tabl
rhinoviru
respiratori
syncyti
viru
rsv
spread
direct
hand
contact
contamin
skin
environment
surfac
follow
selfinocul
viru
nasal
mucosa
conjunctiva
airborn
transmiss
rhinoviru
also
possibl
depend
durat
exposur
infect
individu
transmiss
parainfluenza
viru
piv
direct
persontoperson
contact
larg
particl
aerosol
spread
high
rate
infect
childhood
coupl
frequenc
reinfect
suggest
spread
person
person
evid
suggest
infecti
dose
piv
small
twothird
volunt
develop
flulik
symptom
follow
lowtitr
piv
intranas
challeng
rsv
spread
infect
respiratori
secret
major
rout
transmiss
appear
larg
particl
aerosol
direct
contact
selfinocul
spread
requir
either
close
contact
infect
individu
contamin
hand
follow
introduct
conjunctiva
influenza
tend
spread
smallparticl
aerosol
rel
efficaci
variou
transmiss
rout
natur
condit
viru
unknown
mani
respiratori
virus
exhibit
season
variat
incid
tabl
exact
season
variat
viru
commun
imposs
predict
generalis
may
help
plan
infect
control
strategi
exampl
rsv
influenza
epidem
occur
predominantli
winter
month
peak
preval
januari
march
northern
hemispher
parainfluenza
viru
type
infect
tend
peak
spring
time
wherea
parainfluenza
viru
type
parainfluenza
viru
type
common
autumn
earli
winter
rhinoviru
adenoviru
may
isol
throughout
year
sinc
discoveri
rhinoviru
serotyp
identifi
rel
preval
seem
vari
differ
geograph
area
also
cours
time
virus
common
caus
upper
respiratori
tract
infect
age
group
reservoir
rhinoviru
schoolchildren
transmit
rhinoviru
infect
among
peer
infect
famili
member
home
parainfluenza
viru
common
caus
croup
acut
laryngotracheobronch
young
children
account
caus
common
cold
human
parainfluenza
virus
categoris
type
basi
antigen
differ
transmit
person
person
direct
contact
infecti
respiratori
secret
largeparticl
aerosol
incub
period
day
bone
marrow
transplant
recipi
children
bronchopulmonari
dysplasia
prematur
congenit
heart
diseas
asthma
prone
develop
lower
respiratori
infect
requir
addit
oxygen
supplement
onethird
children
lower
respiratori
infect
due
parainfluenza
thought
develop
secondari
bacteri
infect
coronaviru
account
upper
respiratori
tract
infect
adult
import
featur
coronaviru
infect
shortliv
immun
result
high
reinfect
rate
mode
transmiss
coronaviru
like
due
aerosol
inhal
howev
grow
well
cell
cultur
therefor
virolog
fulli
appreci
recent
novel
coronaviru
sarsassoci
coronaviru
sarscov
propos
caus
outbreak
sever
acut
respiratori
syndrom
sar
viru
induc
symptom
atyp
pneumonia
clinic
indistinguish
similar
syndrom
sever
mortal
rate
report
treatment
yet
identifi
reliabl
success
transmiss
droplet
spread
requir
close
contact
stringent
infect
control
precaut
health
care
institut
broad
isol
measur
affect
commun
intern
surveil
barrier
restrict
travel
led
termin
epidem
juli
peopl
countri
affect
death
report
influenza
viru
infect
account
common
cold
smallparticl
aerosol
spread
implic
sever
outbreak
retain
infect
prolong
period
aerosolis
condit
low
humid
two
featur
distinct
influenza
respiratori
virus
first
influenza
virus
abl
produc
new
strain
popul
lack
immun
lead
worldwid
outbreak
uniqu
featur
antigen
variat
refer
antigen
shift
drift
second
recent
outbreak
human
lethal
influenza
subtyp
suggest
direct
transmiss
human
infect
bird
without
intermedi
host
possibl
avian
influenza
subtyp
caus
high
mortal
kill
chicken
also
human
also
high
proport
amino
acid
chang
gene
product
within
influenza
viru
except
surfac
gene
provid
support
antigen
drift
respiratori
syncyti
viru
rsv
highli
success
human
pathogen
year
age
children
infect
spread
person
person
exposur
contamin
environ
surfac
howev
transmiss
via
aerosolis
droplet
unlik
viru
inactiv
aerosol
incub
day
week
natur
immun
rsv
incomplet
reinfect
rule
adenovirus
first
import
respiratori
virus
discov
tissu
cultur
method
mani
differ
serotyp
associ
incub
period
rang
day
may
long
week
thought
caus
around
common
cold
children
account
high
mortal
neonat
new
pneumoviru
human
metapneumoviru
hmpv
recent
isol
netherland
close
relat
taxonom
rsv
viru
possibl
account
unexplain
respiratori
infect
children
winter
season
seropreval
studi
show
viru
circul
human
least
year
children
age
year
antibodi
viru
age
year
virtual
seroposit
analysi
amplifi
sequenc
show
two
cluster
hmpv
clinic
manifest
hmpv
vari
mild
upper
respiratori
symptom
sever
infect
requir
hospit
admiss
clinic
pictur
indistinguish
form
respiratori
virus
coinfect
hmpv
respiratori
virus
uncommon
role
human
respiratori
infect
still
poorli
understood
new
pathogen
certainli
warrant
longterm
surveil
respiratori
virus
characterist
differ
bacteria
virus
abil
evad
protect
offer
mucociliari
escal
host
nonimmunolog
mechan
addit
pathogenesi
respiratori
virus
fulli
understood
may
due
differ
virus
adopt
differ
manner
infect
infect
differ
site
caus
variabl
degre
damag
respiratori
tract
line
rhinoviru
import
cold
viru
account
upper
respiratori
ill
autumn
commonli
invad
upper
respiratori
tract
minim
nasal
epitheli
damag
wherea
influenza
mainli
caus
extens
damag
lower
airway
due
preval
rhinoviru
studi
common
cold
base
viru
initi
deposit
rhinoviru
eye
nose
lead
attach
viru
host
cell
intercellular
adhes
receptor
back
throat
insid
nasal
epitheli
cell
signific
increas
number
inflammatori
cell
increas
neutrophil
detect
nasal
mucosa
secret
may
reflect
releas
cascad
inflammatori
cytokin
kinin
leukotrien
histamin
tumour
necrosi
factor
rant
regul
activ
normal
tcell
express
secret
partli
respons
symptom
level
kinin
nasal
secret
also
shown
correl
sever
durat
symptom
two
distinct
group
coronavirus
infect
human
distinct
structur
protein
demonstr
immunoelectrophoresi
enzymelink
immunoabsorb
assay
elisa
despit
similar
charg
molecular
weight
utilis
human
aminopeptidas
n
hapn
receptor
gain
entri
respiratori
epithelium
hapn
zincbind
protein
endopeptidas
activ
experiment
studi
human
cell
cultur
pretreat
monoclon
antibodi
hapn
viral
infect
appear
block
howev
gain
entri
respiratori
epithelium
use
two
surfac
glycoprotein
haemagglutininesteras
spike
glycoprotein
despit
differ
pathogenesi
caus
similar
clinic
manifest
reinfect
coronaviru
common
though
underli
reason
clearli
defin
may
due
infect
close
relat
differ
strain
reduct
immun
time
volunt
seroposit
coronaviru
prior
intranas
challeng
complet
protect
symptom
develop
influenza
viru
replic
throughout
respiratori
tract
recover
upper
lower
airway
howev
tend
caus
signific
damag
lower
respiratori
tract
acut
diffus
inflamm
larynx
trachea
bronchi
demonstr
bronchoscopi
peopl
uncompl
influenza
infect
innat
cellular
immun
respons
heighten
infect
proinflammatori
cytokin
interferona
ifna
induc
releas
infect
cell
reach
peak
level
day
follow
infect
coincid
sever
clinic
symptom
score
mucou
product
fever
viral
load
anim
defici
lymphocyt
succumb
sever
influenza
infect
indic
intact
cellular
immun
system
necessari
restrict
overwhelm
infect
rsv
replic
primarili
superfici
layer
respiratori
epithelium
spread
upper
lower
airway
aspir
secret
via
respiratori
epithelium
rsv
infect
caus
signific
damag
epithelium
importantli
mucociliari
escal
inhibit
remov
mucou
cell
debri
lead
occlus
small
bronchiol
interferon
play
pivot
role
inhibit
viral
replic
rsv
infect
notabl
lack
local
interferon
product
rsv
induc
product
interferongamma
level
especi
depress
infant
compar
adult
may
explain
children
would
acquir
rsv
antibodi
age
littl
known
pathophysiolog
hmpv
infect
howev
similar
relat
pneumoviru
human
respiratori
syncyti
viru
rsv
hmpv
appear
tropism
respiratori
epithelium
expert
field
pneumoviru
infect
agre
pathophysiolog
hmpv
infect
like
parallel
rsv
infect
includ
absenc
viraemia
hmpv
proven
difficult
identifi
use
commonli
use
clinic
virolog
procedur
replic
slowli
primari
cynomolgu
monkey
kidney
cell
poorli
vero
cell
cell
human
respiratori
epitheli
cell
line
cell
line
commonli
use
viral
diagnost
laboratori
appear
support
replic
hmpv
commerci
reagent
confirm
presenc
hmpv
yet
avail
current
hmpv
includ
routin
surveil
programm
respiratori
infect
therefor
research
provid
mean
detect
signal
ill
piv
croup
tracheobronch
manifest
fever
hoars
bark
cough
young
children
host
immun
respons
may
play
role
pathogenesi
children
develop
viral
croup
tend
produc
larg
amount
virusspecif
ige
antibodi
rise
ige
level
caus
histamin
releas
trachea
subglott
area
turn
lead
swell
obstruct
upper
airway
understand
pathogenesi
respiratori
virus
import
implic
develop
therapi
common
cold
diagnosi
common
cold
usual
base
patient
clinic
present
clinician
assess
diseas
sometim
diagnosi
less
straightforward
three
reason
first
clinic
featur
common
cold
may
overlap
pharyng
bronchiti
relat
syndrom
share
viral
origin
complic
matter
pharyng
sinus
also
caus
bacteri
infect
second
allerg
diseas
upper
airway
often
clinic
featur
resembl
common
cold
third
infant
young
children
abl
express
symptom
clinician
challeng
distinguish
benign
viral
infect
sever
invas
bacteri
infect
respiratori
virus
typic
clinic
present
may
help
assess
aetiolog
ill
consid
conjunct
epidemiolog
factor
age
clinic
present
patient
season
sometim
virtual
imposs
ascertain
specif
viru
induc
common
cold
individu
patient
clinic
ground
alon
determin
aetiolog
viru
infect
becom
increasingli
essenti
introduct
new
antivir
option
use
new
therapeut
option
problemat
drug
viru
specif
therapi
initi
basi
presumpt
diagnosi
specif
diagnosi
may
import
confirm
initi
impress
determin
length
time
treatment
convers
viral
detect
import
avoid
unnecessari
antibiot
prescript
princip
laboratori
method
respiratori
viru
diagnosi
reli
detect
respiratori
secret
anoth
import
factor
respiratori
viral
diagnosi
submit
appropri
sampl
test
inadequ
improp
specimen
collect
transport
account
largest
sourc
error
accuraci
viral
detect
result
nasal
swab
nasopharyng
aspir
nasal
wash
specimen
gener
consid
specimen
choic
detect
respiratori
virus
obtain
aspir
unpleas
requir
use
suction
devic
train
individu
make
unattract
widespread
clinic
applic
contrast
collect
nasal
swab
simpl
painless
quick
requir
special
equip
skill
personnel
recent
prospect
studi
show
sensit
nasal
swab
compar
nasopharyng
aspir
detect
major
respiratori
virus
tissu
cultur
except
rsv
isol
virus
tissu
cultur
gold
standard
viru
detect
process
clinic
specimen
often
start
addit
antibiot
antifung
prior
inocul
appropri
cell
line
usual
incub
jc
observ
daili
virusinduc
effect
cytopath
effect
cpe
three
major
tissu
cell
line
commonli
use
isol
identifi
respiratori
virus
primarili
monkey
kidney
sensit
piv
influenza
human
fetal
lung
fibroblast
sensit
adenoviru
rhinoviru
continu
cell
line
cell
sensit
adenoviru
rsv
howev
slow
tissu
cultur
viral
detect
make
clinic
impract
especi
rapid
diagnosi
requir
order
initi
appropri
therapi
sinc
serotyp
rhinoviru
accur
diagnosi
method
also
becom
imposs
unreli
major
advantag
antigen
detect
respiratori
secret
immunofluoresc
assay
ifa
enzymelink
immunoabsorb
assay
elisa
perform
rapidli
provid
result
within
h
receiv
specimen
laboratori
ifa
divid
direct
indirect
method
direct
immunofluoresc
utilis
fluorochromelabel
antibodi
specif
viral
protein
antigen
involv
fix
specimen
contain
viral
materi
onto
slide
virusspecif
monoclon
antibodi
label
fluorochrom
bind
antigen
follow
addit
substrat
colour
chang
fluorochrom
induc
turn
detect
fluoresc
microscop
indirect
immunofluorosc
use
unlabel
monoclon
antibodi
bind
viral
antigen
wash
away
bound
monoclon
antibodi
detect
label
antimous
antibodi
use
multipl
antibodi
theori
improv
sensit
detect
multipl
conjug
molecul
attach
virusspecif
antibodi
elisa
similar
ifa
howev
instead
use
fluoresc
label
enzym
label
use
assay
utilis
doubl
antibodi
sandwich
captur
antibodi
specif
viral
antigen
sought
bound
reaction
surfac
specimen
viral
antigen
ad
bind
captur
antibodi
bound
antigen
detect
second
antivir
antibodi
detector
antibodi
detector
antibodi
carri
enzym
label
bound
enzym
produc
colour
chang
colour
chang
detect
photometri
disadvantag
elisa
usual
less
sensit
reagent
avail
limit
number
virus
addit
adult
tend
lower
viral
titr
nasopharyng
aspir
make
sensit
test
understand
lower
serolog
assay
one
oldest
techniqu
diagnost
virolog
detect
antibodi
patient
sera
indic
recent
igm
past
igg
infect
even
import
come
determin
immun
statu
individu
evalu
immun
respons
vaccin
serum
specimen
choic
serolog
diagnosi
pair
serum
specimen
week
apart
requir
diagnosi
current
recent
viral
infect
demonstr
seroconvers
neg
posit
igg
antibodi
respons
detect
presenc
virusspecif
igm
diagnost
primari
viral
infect
fourfold
increas
igg
titr
acut
convalesc
sera
usual
week
apart
may
indic
recent
infect
due
reinfect
reactiv
yet
test
retrospect
littl
impact
patient
immedi
care
addit
result
serolog
test
viralspecif
antibodi
must
interpret
care
number
reason
first
may
delay
lack
product
serum
antibodi
especi
immunocompromis
second
recurr
infect
signific
rise
antibodi
may
appar
third
antibodi
level
remain
elev
long
period
time
follow
infect
therefor
clinic
statu
patient
taken
account
molecular
techniqu
utilis
viral
nucleic
acid
antigen
detect
system
fundament
differ
serolog
assay
sinc
detect
compon
organ
rather
demonstr
evid
past
presenc
therefor
case
nucleic
acid
detect
integr
specimen
import
wherea
case
tissu
cultur
whole
viru
often
requir
respiratori
virus
possess
either
rna
dna
therefor
essenti
know
structur
individu
viru
order
develop
molecular
techniqu
identifi
nucleic
acid
polymeras
chain
reaction
pcr
dramat
alter
detect
characteris
viral
nucleic
acid
identifi
target
organ
specimen
low
concentr
nuclear
materi
matter
hour
dna
virus
pcr
amplif
straightforward
principl
demonstr
fig
howev
rna
virus
genom
unstabl
use
pcr
rna
convert
complementari
dna
cdna
use
revers
transcriptas
retrovir
enzym
make
precis
copi
mrna
pcr
perform
normal
manner
amplifi
genom
materi
dna
amplifi
detect
basi
size
gel
electrophoresi
southern
blot
resolv
nucleic
acid
transfer
membran
react
nucleic
acid
probe
specif
desir
pcr
product
newer
techniqu
viru
identif
nucleic
acid
sequencebas
amplif
nasba
shown
fig
isotherm
nucleic
acid
amplif
method
amplifi
rna
manner
analog
amplif
dna
pcr
nasba
reaction
mixtur
contain
oligonucleotid
primer
three
enzym
avian
myelobastosi
virusrevers
transcriptas
amvrt
rnase
h
rna
polymeras
targetspecif
amplif
process
take
place
jc
result
exponenti
amplif
product
within
h
produc
singlestrand
rna
opposit
sens
origin
target
detect
nasba
product
report
use
probecaptur
hybridis
electrochemiluminesc
ecl
recent
realtim
detect
use
molecular
beacon
describ
molecular
techniqu
number
advantag
convent
method
current
utilis
respiratori
viral
detect
tradit
viru
cultur
serolog
analysi
may
requir
week
result
avail
direct
antigen
detect
variabl
sensit
specif
molecular
assay
particular
advantag
start
materi
avail
acellular
swab
materi
surveil
sampl
may
low
copi
number
target
analys
nucleic
acid
amplif
potenti
produc
rapid
turnov
result
allow
diagnost
virolog
impact
patient
manag
avoid
inappropri
prescript
antibiot
allow
proper
use
antivir
comparison
molecular
techniqu
convent
method
viral
detect
shown
tabl
advantag
nasba
assay
compar
pcr
method
continu
isotherm
process
requir
thermocycl
constant
temperatur
throughout
amplif
reaction
enabl
step
reaction
amplifi
target
rna
dna
exponenti
thu
nasba
reaction
effici
pcr
method
restrict
binari
increas
per
cycl
exist
divers
viral
serotyp
caus
common
cold
made
vaccin
prepar
difficult
frequent
mutat
viral
protein
rna
virus
exampl
genet
drift
shift
influenza
hamper
prevent
ill
influenza
vaccin
commerci
avail
vaccin
virtual
split
product
purifi
subunit
vaccin
use
around
world
strain
either
b
use
immunis
select
yearli
base
recommend
world
health
organis
conjunct
nation
public
health
institut
recent
vaccin
contain
antigen
two
influenza
subtyp
strain
current
circul
subtyp
one
influenza
b
viru
wane
vaccineinduc
immun
time
requir
annual
reimmunis
even
vaccin
antigen
unchang
current
recommend
influenza
vaccin
uk
offer
age
chronic
heart
respiratori
renal
diseas
diabet
immunosuppress
nation
polici
also
state
live
longstay
residenti
nurs
home
prioritis
vaccin
despit
wide
avail
vaccin
influenza
still
caus
excess
death
per
year
uk
rhinoviru
serotyp
unlik
unifi
vaccin
develop
howev
use
antivir
chemoprophylaxi
may
practic
valu
topic
applic
interferon
nose
shown
effect
reduc
incid
cold
peopl
expos
other
fresh
cold
strategi
reduc
overal
risk
cold
almost
elimin
proven
rhinoviru
cold
contact
develop
rsv
vaccin
hamper
experi
formalininactiv
whole
rsv
vaccin
caus
rsv
vaccine
becom
hospitalis
compar
control
well
two
fatal
current
major
research
focus
prophylaxi
use
humanis
mous
monoclon
antibodi
palizivumab
shown
reduc
rate
rsvassoci
hospitalis
prematur
infant
howev
use
wider
popul
requir
research
current
licens
parainfluenza
vaccin
date
formalininactiv
vaccin
gener
abl
prevent
piv
infect
soon
abandon
present
recombin
bovin
human
attenu
vaccin
evalu
anim
model
vector
deliveri
viral
antigen
rsvg
rsvf
protein
bival
vaccin
combin
provid
high
level
resist
challeng
rsv
anim
model
convent
method
vaccin
via
intramuscular
subcutan
rout
mucos
immunis
recent
explor
repres
attract
manner
deliv
vaccin
fast
simpl
noninvas
carri
unskil
individu
use
mucos
vaccin
seem
logic
respiratori
viral
infect
initi
start
mucos
site
therefor
induc
local
immun
help
arrest
infect
earli
phase
system
complic
aris
thu
far
inconclus
evid
support
use
vitamin
c
extract
plant
echinacea
common
cold
prevent
daili
supplement
larg
dose
vitamin
c
seem
prevent
common
cold
howev
seem
modest
reduct
number
symptom
day
individu
establish
cold
symptom
larger
dose
greater
effect
echinacea
current
avail
data
studi
conduct
adult
popul
show
posit
find
treatment
prevent
upper
respiratori
infect
howev
variat
design
clinic
trial
echinacea
prepar
taken
account
zinc
shown
possess
antivir
properti
vitro
differ
prepar
zinc
propos
treatment
common
cold
zinc
lozeng
appear
posit
effect
adult
neg
effect
children
term
durat
sever
common
cold
symptom
zinc
nasal
spray
appear
reduc
total
symptom
score
effect
durat
common
cold
recent
research
show
zinc
nasal
gel
reduc
median
time
cold
resolut
compar
placebo
day
vs
day
p
decreas
median
time
resolut
nasal
congest
nasal
drainag
hoars
sore
throat
far
effect
therapeut
option
avail
treat
common
cold
sinc
mani
virus
involv
aetiolog
recent
studi
focus
three
area
treatment
common
cold
symptomat
manag
pharmacolog
treatment
antivir
agent
disturb
symptom
common
cold
nasal
discharg
stuffi
alpha
agonist
either
alon
combin
nonsteroid
antiinflammatori
drug
effect
reduc
nasal
blockag
rhinorrhoea
nasal
decongest
improv
cold
symptom
adult
improv
nasal
patenc
children
howev
side
effect
rebound
obstruct
nasal
epitheli
dri
imped
use
firstgener
antihistamin
shown
favour
effect
upon
nasal
symptom
adult
studi
probabl
anticholinerg
effect
topic
applic
ipratropium
anticholinerg
drug
moder
dose
minim
absorb
across
biolog
membran
reduc
rhinorrhoea
sneez
cold
routin
use
cough
medic
healthi
children
adult
pose
potenti
problem
use
caution
patient
chronic
obstruct
airway
diseas
nonsteroid
antiinflammatori
drug
shown
reduc
symptom
rhinoviru
infect
reduc
fever
headach
sore
throat
cough
may
prostaglandin
amongst
inflammatori
mediat
respons
pathogenesi
rhinoviru
cold
intranas
interferon
alon
practic
treatment
option
common
cold
howev
use
combin
ipratropium
nonsteroid
antiinflammatori
drug
significantli
reduc
symptom
experiment
cold
amantadin
convent
antivir
influenza
howev
strainspecif
effect
influenza
common
side
effect
insomnia
poor
concentr
irrit
replac
newer
agent
zanamivir
oseltamivir
licens
treatment
influenza
b
earli
initi
therapi
ie
within
hour
onset
symptom
reduc
durat
common
cold
symptom
day
zanamivir
poor
oral
bioavail
intranas
applic
shown
effect
treat
experiment
influenza
infect
reduct
symptom
caus
viru
shed
develop
otiti
media
ribavarin
synthet
guanosin
nucleosid
broad
spectrum
antivir
activ
approv
treatment
rsvrelat
respiratori
infect
children
sinc
approv
therapi
lower
respiratori
tract
diseas
caus
rsv
potenti
benefit
ribavarin
therapi
includ
inhibit
rsvspecif
ige
product
nasal
secret
associ
develop
hypoxaemia
wheez
improv
pulmonari
function
control
studi
also
show
use
ribavarin
effect
reduc
clinic
sever
score
durat
mechan
ventil
supplement
oxygen
use
day
hospitalis
although
rhinoviru
major
caus
cold
vast
amount
serotyp
made
develop
antivir
problemat
rhinoviru
serotyp
gain
entri
epitheli
cell
use
cellular
receptor
blockad
receptor
experiment
studi
show
reduc
infect
sever
studi
requir
treatment
option
becom
wide
avail
contrari
common
belief
evid
use
antibiot
treatment
cold
inappropri
antibiot
use
induc
signific
side
effect
increas
colonis
resist
organ
recent
discoveri
human
metapneumoviru
develop
molecular
techniqu
viral
detect
repres
excit
time
studi
common
cold
research
host
inflammatori
respons
use
combin
therapi
may
provid
longterm
treatment
option
debilit
diseas
meantim
clinician
concentr
patient
educ
regard
vaccin
avoid
unnecessari
antibiot
prescript
